North-methanocarbathymidine

North-methanocarbathymidine
Clinical data
Trade namesN-MCT
Legal status
Legal status
  • US: Investigational drug
Identifiers
IUPAC name
  • 1-[(1S,2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-bicyclo[3.1.0]hexanyl]-5-methylpyrimidine-2,4-dione
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC12H16N2O4
Molar mass252.270 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@]3([C@@H]2C3)CO)O
InChI
  • InChI=1S/C12H16N2O4/c1-6-4-14(11(18)13-10(6)17)8-2-9(16)12(5-15)3-7(8)12/h4,7-9,15-16H,2-3,5H2,1H3,(H,13,17,18)/t7-,8+,9+,12+/m1/s1
  • Key:NOWRLNPOENZFHP-ARHDFHRDSA-N

North-Methanocarbathymidine (N-MCT) is an antiviral drug which is an analogue of thymidine, and shows activity against herpesviruses, orthopoxviruses and HIV,[1][2][3][4] though it has not been introduced into clinical use.

References

  1. Zhu W, Burnette A, Dorjsuren D, Roberts PE, Huleihel M, Shoemaker RH, et al. (December 2005). "Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus". Antimicrobial Agents and Chemotherapy. 49 (12): 4965–73. doi:10.1128/AAC.49.12.4965-4973.2005. PMC 1315933. PMID 16304159.
  2. Marquez VE, Hughes SH, Sei S, Agbaria R (September 2006). "The history of N-methanocarbathymidine: the investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent". Antiviral Research. 71 (2–3): 268–75. doi:10.1016/j.antiviral.2006.04.012. PMID 16730077.
  3. Prichard MN, Kern ER (September 2010). "Antiviral Activity of 4'-thioIDU and Thymidine Analogs against Orthopoxviruses". Viruses. 2 (9): 1968–83. doi:10.3390/v2091968. PMC 3185742. PMID 21994716.
  4. De Clercq E (November 2013). "Highlights in antiviral drug research: antivirals at the horizon". Medicinal Research Reviews. 33 (6): 1215–48. doi:10.1002/med.21256. PMC 7168470. PMID 22553111.